The International Regulatory Peptide Society (IRPS) has been an affiliated member of IUPHAR since 2019. The next biannual symposium of IRPS will be held in the venues of Stirling University, Stirling, Scotland, UK during August 1-5, 2022 (for details, please visit www.RepPep.org).
The symposium will cover various aspects of regulatory peptides, particularly on advances in basic research on regulatory peptide physiology and pharmacology, leading to accelerated translation to peptide-based therapeutics.
The biannual symposia were named “International Symposium of Gastrointestinal Hormones” during a period of 1976 – 1994 and renamed “International Symposium on Regulatory Peptides” since 1996, which reflects the evolution of regulatory peptide discovery. Figure 1 shows the extraordinary evolution of these molecules from gut hormones, to hypothalamic hypophysiotropic factors, to brain neuropeptides, and finally encompassing systems physiology as regulatory peptides in full.
Fig. 1: Milestones of regulatory peptides’ discovery and RepPep symposia during “era of hormones” (1902-1975), “era of gut hormones” (1976-1994) and “era of regulatory peptides” (1996-2021). Note: the list of regulatory peptides shown is illustrative but not comprehensive (for further information, see Regulatory Peptides 177 (2012) by Rehfeld J.F., Handbook of Biologically Active Peptides 2nd edition (2013) by Kastin A.J., Genome Biology 3 (2002) by Nichols R, Journal of Proteome Research 2 (2003) by Svensson M et al. and Nature Reviews Drug Discovery 20 (2021) by Muttenthaler M et al.).
It ought to be remarked that the milestones of regulatory peptides’ discovery should also include, at least, the identification, cloning and characterizations of receptors; the elucidation of physiological functions and mechanisms; the development in diagnostics and therapy; and the involvement in pathophysiology. These themes have been covered throughout all RepPep symposia during the past 47 years and will be even more highlighted in the upcoming symposium.
Now with so many GPCR structures being elucidated; so many peptides approved by FDA for metabolic disorders; so many strides in therapeutics and diagnostics; and so many peptidergic circuits discovered in brain, we believe this is truly a time of renaissance for regulatory peptides. The mission of IRPS is to make the best scientific and educational contribution for public benefit, which is well aligned with the objectives of IUPHAR. It is our hope that the partnership between IRPS and IUPHAR will accelerate peptide-centric drug discovery.
The history of RegPep symposia is a history of the immense significance. All are warmly welcome to join RegPep24 and let’s contribute together to a new era of regulatory peptides!
Duan Chen, IRPS Advisory Council Member and IUPHAR GI Section Past Chair and Executive Committee Member
Jens F. Rehfeld, IRPS Distinguished Member
Limei Zhang, President of IRPS
Bob Millar, President Elect of IRPS
Lee E. Eiden, Chair of programme committee of RegPep24 and Past President of IRPS